Sales of biogenerics in US, Europe to soar-study LONDON (Reuters)

Sales of biogenerics in US, Europe to soar-study
LONDON (Reuters) - Copycat versions of expensive biotech drugs could see $16.4 billion in sales in the United States and Europe by 2011 once regulatory curbs on so-called biogenerics use are gone, a study showed on Monday.